Mareque, MaríaMingot-Castellano, María EvaLópez-Fernández, María FernandaÁlvarez-Román, María TeresaOyagüez, Itziar2023-02-082023-02-082020-04-16http://hdl.handle.net/10668/15295This study estimated the cost of prophylaxis with activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa) in surgical patients with haemophilia A and inhibitors in Spain. A decision-analytic model was developed to estimate the cost to the Spanish National Health System of providing haemostatic coverage in this haemophilia population, with age distribution and average weight derived from the literature, and the annual number of surgeries (0.33 per patient) from local data. Drug costs were calculated from official ex-factory prices with a 7.5% mandatory deduction and recommended dosing regimens. The estimated average costs per patient were €10 100.73 (aPCC) and €14 265.89 (rFVIIa) for dental extraction, €24 043.88 (aPCC) and €62 301.08 (rFVIIa) for minor surgery and €126 595.81 (aPCC) and €347 731.09 (rFVIIa) for major surgery. Assuming an estimated 23 annual surgeries in this population (N = 69), distributed as 19% dental extraction, 50% minor surgery and 31% major surgery, the total annual cost of prophylaxis was €1 209 682.35 with aPCC and €3 221 929.28 with rFVIIa. aPCC costs were 62.5% lower than rFVIIa. Assuming potential clinical equivalence, aPCC is a potentially cost-saving option for surgical patients with haemophilia A and inhibitors.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/coagulation disordersBlood Coagulation Factor InhibitorsClinical Decision-MakingCost-Benefit AnalysisDisease ManagementDrug CostsFactor VIIaHealth Care SurveysHemophilia AHemorrhageHumansIsoantibodiesRecombinant ProteinsSpainSurgical Procedures, Operativeresearch article32220097open access10.1111/ejh.134141600-0609PMC7383573https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13414https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383573/pdf